Sunday 18 October 2026
Export KYTX’s income statement to Excel — free account
Kyverna Therapeutics, Inc.
KYTX Healthcare Biotechnology
Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million. In the quarter to June 2026, EPS grew 35.1%, free cash flow fell 27.1% and total debt rose 95,603.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.67
0.30
−5.03%
Follow KYTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (3.14) |
P/FCF ratio |
— | — | — | 0.00 |
P/Operating CF |
— | — | — | (1.09) |
P/B ratio |
— | — | — | 0.00 |
Price to Tangible BV |
— | — | — | 0.00 |
EV/Sales |
— | — | — | 0.00 |
EV/EBITDA |
— | — | — | 0.60 |
EV/Operating CF |
— | — | — | 0.69 |
EV/FCF |
— | — | — | 0.69 |
Quick Ratio |
7.65 | 8.47 | 2.90 | 4.29 |
Current Ratio |
7.75 | 8.61 | 3.05 | 4.45 |
Net Debt/EBITDA |
1.51 | 2.03 | 0.93 | 1.77 |
Debt/Assets |
8.42% | 0.05% | 1.22% | 1.61% |
Debt/Equity |
0.11 | 0.00 | (0.01) | (0.01) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.95 | 0.90 | 0.87 | 1.25 |
Capex/Depreciation |
0.04 | (1.03) | (0.36) | (0.73) |
Interest Coverage |
(347.29) | (1,004.25) | (333.72) | (452.06) |
| (64.67%) | (188.59%) | 58.78% | 0.00% | |
| (53.91%) | (67.12%) | (84.95%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(65.04%) | (48.99%) | (139.96%) | (65.86%) |
Average Days of Receivables |
— | — | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 404.30% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 113.98% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 13.22% |
Graham Net Nets |
— | — | — | (7.22) |
Graham Number |
— | — | — | 0.00 |
Earnings Yield |
— | — | — | (298.55%) |
Free Cash Flow Yield |
— | — | — | (262.27%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 15.42 |
Operating CF per Share |
(3.47) | (2.98) | (77.76) | (79.28) |
Capex per Share |
0.00 | (0.06) | (0.92) | (1.69) |
Free Cash Flow per Share |
(3.47) | (3.04) | (78.68) | (80.97) |
Cash per Share |
6.31 | 7.46 | 85.38 | 112.67 |
Shareholders Equity per Share |
5.25 | 6.95 | (194.95) | (162.45) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.25 | 6.95 | (194.95) | (162.45) |
Free Cash Flow |
(153.65) | (116.45) | (53.03) | (36.88) |
Working Capital |
246.47 | 256.85 | 40.81 | 41.30 |
Capital Expenditures |
0.07 | (2.20) | (0.62) | (0.77) |
Net Current Asset Value |
221.40 | 252.54 | (145.93) | (87.67) |
EV/EBIT |
— | — | — | 0.58 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.11 |
Price to Operating Income |
— | — | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
1.16 | 0.64 | 0.73 | 0.41 |
Cash ROIC |
(28.65%) | (21.07%) | 72.71% | 170.77% |
Accounts Receivable Turnover |
— | — | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
4.97 | 4.49 | 2.90 | — |
Average Assets |
299.24 | 189.92 | 71.06 | — |
Average Common Equity |
249.43 | 67.60 | (102.70) | — |
Columns are period end dates